Summary of urinary markers for bladder cancer

 Table 1.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702217/#:~:text=To%20date%2C%20the%20only%20urinary,follow%2Dup%20of%20bladder%20cancer.

Summary of urinary markers for bladder cancer

Test (Manufacturer) Marker detected Assay type FDA approval

Cytology Tumor cells Microscopy N/A

BLCA-4

(Eichrom Technologies) Nuclear matrix protein Sandwich ELISA (rabbit polyclonal antibody) –

BTA stat®

(Polymedco) Complement factor H-related protein and complement factor H Immunoassay or point-of-care For diagnosis & follow-up

BTA TRAK®

(Polymedco) Complement factor H-related protein and complement factor H Sandwich ELISA For diagnosis & follow-up

CYFRA 21-1

(Bio International; Roche Diagnostics) Cytoskeletal protein (cytokeratin 19) Immunoradiometric assay or ELISA –

DD23

(UroCor Labs) 185-kDa tumor associated antigen Immunocytochemistry –

NMP22/BladderChek®

(Alere) Nuclear mitotic apparatus protein Sandwich ELISA or point-of-care For diagnosis & follow-up

Survivin

(Fujirebio Diagnostics) Inhibitor of apoptosis gene Bio-dot test (rabbit polyclonal antibody) –

UBC™

(IDL Biotech) Cytoskeletal proteins (cytokeratin 8 and 18) Sandwich ELISA or point-of-care –

ImmunoCyt™/uCyt+™

(Scimedx) Carcinoembryonic antigen, two bladder tumor cell-associated mucins Immunocytochemistry For follow-up

UroVysion™

(Abbott, Vysis) Alterations in chromosomes 3, 7, 17, and 9p21 FISH For diagnosis & follow-up

Open in a separate window

ELISA, enzyme-linked immunosorbent assay; FISH, fluorescence in-situ hybridization